NIKE names Pfizer CFO David Denton as CFO; Matthew Friend steps down, Q4 tariff refund benefit
NIKE said David Denton, currently CFO of Pfizer, will become Executive Vice President and Chief Financial Officer, replacing Matthew Friend, effective in August 2026. The company also said its fourth quarter fiscal 2026 results, due June 30, will include a one-time tariff refund benefit that was not in its previous guidance; excluding that benefit, results are expected to be generally in line with guidance.
Key points
- Denton takes over as CFO effective August 16, 2026 per the 8-K; the press release says August 17
- Friend becomes an advisor to the CEO and stays with NIKE through his separation on September 4, 2026, with a $2.0 million lump sum transition benefit subject to conditions
- Denton's offer includes a $1.45 million base salary, a $11.5 million annual target long-term incentive award, and a $7.25 million new hire cash award
- Fourth quarter fiscal 2026 results, reported June 30, include a tariff refund benefit not in prior guidance; excluding it, results are expected to be generally in line
The filing
Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 23, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.